{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T08:17:30Z","timestamp":1794903450964,"version":"4.9.1"},"reference-count":33,"publisher":"Informa UK Limited","issue":"29","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,12,8]]},"DOI":"10.1080\/14796694.2025.2589057","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:38:49Z","timestamp":1763984329000},"page":"3739-3748","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers"],"prefix":"10.1080","volume":"21","author":[{"given":"Masafumi","family":"Ikeda","sequence":"first","affiliation":[{"name":"National Cancer Center Hospital East","place":["Kashiwa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus-Alexander","family":"W\u00f6rns","sequence":"additional","affiliation":[{"name":"Klinikum of the University Witten\/Herdecke","place":["Dortmund, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Akce","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center of University of Alabama at Birmingham, Heersink School of Medicine","place":["Birmingham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiun","family":"Hsu","sequence":"additional","affiliation":[{"name":"National Taiwan University Cancer Center","place":["Taipei, Taiwan"]},{"name":"National Taiwan University Hospital","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall C.","family":"Tebbutt","sequence":"additional","affiliation":[{"name":"Austin Health","place":["Heidelberg, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Casadei-Gardini","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University School of Medicine, IRCCS San Raffaele Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janvi","family":"Sah","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Gaithersburg, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mufiza","family":"Farid-Kapadia","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Mississauga, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heide A.","family":"Stirnadel-Farrant","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Cambridge, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Paskow","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Gaithersburg, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Baur","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Gaithersburg, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Melillo","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Gaithersburg, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Schmidt","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Cambridge, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Daktera","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[{"name":"University of Toronto","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"e_1_3_6_3_1","unstructured":"American Cancer Society. Survival rates for bile duct cancer. 2024 [cited 2024 Aug 16]. Available from: https:\/\/www.cancer.org\/cancer\/types\/bile-duct-cancer\/detection-diagnosis-staging\/survival-by-stage.html"},{"key":"e_1_3_6_4_1","unstructured":"American Cancer Society. Survival rates for gallbladder cancer. 2024 [cited 2024 Aug 16]. Available from: https:\/\/www.cancer.org\/cancer\/types\/gallbladder-cancer\/detection-diagnosis-staging\/survival-rates.html"},{"key":"e_1_3_6_5_1","unstructured":"National Institutes of Health. Cancer stat facts: liver and intrahepatic bile duct cancer. 2021 [cited 2021 Jul 6]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/livibd.html"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2019.06.007"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010048"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00153-7"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070"},{"key":"#cr-split#-e_1_3_6_14_1.1","unstructured":"US Food and Drug Administration. Imfinzi (durvalumab): highlights of prescribing information. [updated 2025 Feb 2"},{"key":"#cr-split#-e_1_3_6_14_1.2","unstructured":"cited 2025 Jun 17]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761069s035lbl.pdf"},{"key":"#cr-split#-e_1_3_6_15_1.1","unstructured":"European Medicines Agency. Imfinzi (durvalumab): summary of product characteristics. [updated 2025 Feb 2"},{"key":"#cr-split#-e_1_3_6_15_1.2","unstructured":"cited 2025 Jun 17]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imfinzi-epar-product-information_en.pdf"},{"key":"e_1_3_6_16_1","unstructured":"European Medicines Agency. Imjudo (tremelimumab): summary of product characteristics. [cited 2023 Aug 15]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imjudo-epar-product-information_en.pdf"},{"key":"#cr-split#-e_1_3_6_17_1.1","unstructured":"US Food and Drug Administration. Imjudo (tremelimumab-actl): highlights of prescribing information. [Last updated 2023 Aug 15"},{"key":"#cr-split#-e_1_3_6_17_1.2","unstructured":"cited 2025 Jun 17]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761289lbl.pdf"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1007"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.285"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101567"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103647"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.506"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02745"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.501"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15641"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114199"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020314"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020305"},{"key":"e_1_3_6_29_1","unstructured":"ClinicalTrials.gov. A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma (EMERALD-1). 2024 [cited 2024 May 31]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03778957"},{"key":"e_1_3_6_30_1","unstructured":"ClinicalTrials.gov. Assess efficacy and safety of durvalumab alone or combined with bevacizumab in high risk of recurrence HCC patients after curative treatment (EMERALD-2). 2023 [cited 2025 Jun 17]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03847428"},{"key":"e_1_3_6_31_1","unstructured":"ClinicalTrials.gov. Evaluate durvalumab and tremelimumab \u00b1 lenvatinib in combination with TACE in patients with locoregional HCC (EMERALD-3). 2024 [cited 2024 May 31]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05301842"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4186"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2589057","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2025.2589057","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2589057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:31:37Z","timestamp":1794900697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2589057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":33,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2025,12,8]]}},"alternative-id":["10.1080\/14796694.2025.2589057"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2589057","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-07-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}